文献速递冠心病血脂与心血管预防

经皮冠状动脉介入治疗抗血栓治疗的40年演变

Evolution of antithrombotic therapy in patients undergoing percutaneous coronary intervention: a 40-year journey.
PubMed 文献 · Eur Heart J · 2021-01-01

本文综述了自1977年经皮冠状动脉介入治疗(PCI)引入以来抗血栓药物的发展历程。文章概述了抗血栓药理学的重要里程碑,这些里程碑塑造了当今临床实践,同时指出了知识空白和未来方向。

要点

  • 抗血栓药物贯穿PCI患者管理全程,从手术到长期预防。
  • 40年来药物和器械技术进步反映了对冠心病病理生理的更深入理解。
  • 综述旨在总结抗血栓药理学里程碑并指出知识空白与未来方向。

核心结论

  • PCI的广泛开展离不开抗血栓治疗的同步演进。
  • 抗血栓药物是PCI患者管理的基础,涵盖围手术期和长期预防。

研究设计与样本

  • 综述文章,回顾PCI抗血栓治疗40年演变。

主要发现

  • 过去40年介入心脏病学在药物和器械技术方面取得显著进步。
  • 这些进步反映了对冠心病病理生理及手术和器械相关不良事件机制的逐步理解。

临床怎么用

  • 抗血栓治疗应贯穿PCI患者从手术到长期心血管事件预防的全过程。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Since its introduction in 1977, percutaneous coronary intervention has become one of the most commonly performed therapeutic procedures worldwide. Such widespread diffusion, however, would have not been possible without a concomitant evolution of the pharmacotherapies associated with this intervention. Antithrombotic agents are fundamental throughout the management of patients undergoing coronary stent implantation, starting from the procedure itself to the long-term prevention of cardiovascular events. The last 40 years of interventional cardiology have seen remarkable improvements in both drug therapies and device technologies, which largely reflected a progressive understanding of the pathophysiological mechanisms of coronary artery disease, as well as procedure- and device-related adverse events. The purpose of this article is to provide an overview of the important milestones in antithrombotic pharmacology that have shaped clinical practice of today while also providing insights into knowledge gaps and future directions.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Cao D, Chandiramani R, Chiarito M, et al. Evolution of antithrombotic therapy in patients undergoing percutaneous coronary intervention: a 40-year journey. Eur Heart J. 2021. PMID: 33367641. doi:10.1093/eurheartj/ehaa824

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。